Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab

Recent developments in immune checkpoint inhibitors (ICIs) have provided new treatment strategies for advanced cancer. However, ICIs lead to an imbalance between T cell–mediated inflammatory responses and immune tolerance in the myocardium. Here we report the first case that implicates the contribut...

Descripción completa

Detalles Bibliográficos
Autores principales: Oishi, Hideo, Morimoto, Ryota, Shimoyama, Yoshie, Kuroda, Kei, Urata, Toru, Kondo, Toru, Okumura, Takahiro, Bando, Yasuko K., Akiyama, Masashi, Murohara, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Mini-Focus Issue: Cardiomyopathies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299122/
https://www.ncbi.nlm.nih.gov/pubmed/34317084
http://dx.doi.org/10.1016/j.jaccas.2020.07.028
Descripción
Sumario:Recent developments in immune checkpoint inhibitors (ICIs) have provided new treatment strategies for advanced cancer. However, ICIs lead to an imbalance between T cell–mediated inflammatory responses and immune tolerance in the myocardium. Here we report the first case that implicates the contribution of ICI-induced vasculitis to myocardial injury. (Level of Difficulty: Intermediate.)

Ejemplares similares